Proterris

Proterris is a clinical-stage firm based in Boston, Massachusetts, specializing in therapeutic applications of inhaled and small-molecule carbon monoxide. The company has developed a strong intellectual property position focusing on the treatment of conditions such as delayed graft function, acute liver failure, and non-alcoholic steatohepatitis. Proterris is also exploring additional therapeutic opportunities in areas including acute kidney injury, renal fibrosis, and idiopathic pulmonary fibrosis. Their innovative approach aims to provide effective treatment options for patients suffering from a variety of fibrotic and ischemia-reperfusion injury disorders.

http://proterris.com

https://crunchbase.com/organization/alfama-inc

https://linkedin.com/company/proterris

https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=429704467

Joseph Wager

Co-Founder and Vice President of Business Development

Jeffrey D. Wager

CEO, Chairman and Co-Founder

1 past transactions

Alfama

Acquisition in 2017

Alfama is a pharmaceutical company that develops Carbon Monoxide-Releasing Molecules (CORMs) for therapy. The company has produced hundreds of CORMs and obtained exceptional results in various animal models of chronic and acute human diseases. CORMs have the potential to expand CO-based therapy to a wide range of high-value indications, can be administered orally or intravenously, and offer a very attractive therapeutic window and safety profile. It is based in Boston, Massachusetts.

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.